Loading clinical trials...
Loading clinical trials...
A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)
Conditions
Interventions
Alprostadil
Placebo
Locations
4
United States
Diagnamics, Inc.
Encinitas, California, United States
University of Michigan Scleroderma Program - Division of Rheumatology/Dept. of Internal Medicine
Ann Arbor, Michigan, United States
Cleveland Clinic
Cleveland, Ohio, United States
Scleroderma Research Center - University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States
Start Date
November 1, 2014
Primary Completion Date
June 1, 2015
Completion Date
December 1, 2015
Last Updated
March 22, 2016
Lead Sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions